Actis Giovanni C, Pellicano Rinaldo, Rosina Floriano
Giovanni C Actis, Floriano Rosina, Hepatogastroenterology Division, Ospedale Gradenigo, 10153 Torino, Italy.
World J Gastrointest Pharmacol Ther. 2015 May 6;6(2):10-6. doi: 10.4292/wjgpt.v6.i2.10.
Despite the level of sophistication they have reached nowadays, the available tools for treatment of inflammatory bowel disease (IBD) can at best chronicize the disease but not cure it. Chances to make leap forward from this hold-back may include designs to reach personalized treatment strategies taking advantage of modern genome associated studies, and shift resources towards unfolding inciting pathogenetic steps rather than continuing to develop drugs that address down-stream phenomena. We have arbitrarily chosen to scrutinize a few projects that may make their way in 2015 and mark the history of IBD research. The list includes: the role of appendix as a regulating factor in pathogenesis of ulcerative colitis/proctitis; the reappraisal of (auto)immune phenomena in the era of microbiome; projects to treat IBD by stem cell infusion; recognition of the crucial pathogenetic role of gut microbiome, and attempts to modify it to treat enteric diseases, from clostridium difficile infection to IBD.
尽管如今治疗炎症性肠病（IBD）的可用工具已达到相当复杂的程度，但这些工具充其量只能使疾病慢性化，而无法治愈。突破这一困境的机会可能包括利用现代基因组相关研究设计个性化治疗策略，并将资源转向揭示引发疾病的致病步骤，而不是继续开发针对下游现象的药物。我们随意挑选了一些可能在2015年取得进展并载入IBD研究史册的项目。清单包括：阑尾在溃疡性结肠炎/直肠炎发病机制中作为调节因子的作用；微生物组时代对（自身）免疫现象的重新评估；通过干细胞输注治疗IBD的项目；认识到肠道微生物组的关键致病作用，以及尝试对其进行调节以治疗从艰难梭菌感染到IBD等肠道疾病。
